Dopamine Receptor Subtype-Selective Drugs: D1-Like Receptors
作者： David E. Nichols
DOI: 10.1007/978-1-60327-333-6_4
关键词:
摘要: A survey is presented of the development dopamine D1 receptor-selective drugs, including agonists and antagonists. It noted that there are presently no ligands specific for vs D5 receptor isoforms. general discussion on structure–activity features D1/D5 selective agents, with conclusions developed all known full must contain a catechol moiety and, in addition, require presence hydrophobic (typically phenyl ring) region adjacent to beta side chain carbon embedded fragment. This latter structural feature so crucial when added noncatechol ergoline it gave D1-selective partial agonist. Present evidence indicates may be therapeutically useful treatment Parkinson’s disease, as well improving cognition working memory schizophrenia age-related cognitive decline. No agonist has yet been commercialized, seems largely due difficulties oral bioavailability catechol-containing drugs.
springer.com
sci-hub.st 参考文章(85)
Uros Laban, Synthesis of 4-aminomethylchromans: Novel dopamine D 2-selective agonists ,(2004)
John D. McDermed, Harold S. Freeman, Robert M. Ferris, ENANTIOSELECTIVITY IN THE BINDING OF (+)- AND (−)-2-AMINO-6,7-DIHYDROXY-1,2,3,4-TETRAHYDRONAPHTHALENE AND RELATED AGONISTS TO DOPAMINE RECEPTORS Catecholamines: Basic and Clinical Frontiers#R##N#Proceedings of the Fourth International Catecholamine Symposium, Pacific Grove, California, September 17-22, 1978. pp. 568- 570 ,(1979) , 10.1016/B978-1-4832-8363-0.50174-9
T N Chase, M Gillespie, J Fang, P J Blanchet, R Gammans, M M Mouradian, K W Locke, L Sabounjian, Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson's disease. Clinical Neuropharmacology. ,vol. 21, pp. 339- 343 ,(1998)
Russell Alan Grubbs, Synthesis of novel dopaminergic ligands: A bioisosteric approach ,(2000)
N.J. Pollock, A.M. Manelli, C.W. Hutchins, M.E. Steffey, R.G. MacKenzie, D.E. Frail, Serine mutations in transmembrane V of the dopamine D1 receptor affect ligand interactions and receptor activation Journal of Biological Chemistry. ,vol. 267, pp. 17780- 17786 ,(1992) , 10.1016/S0021-9258(19)37112-1
C D Strader, I S Sigal, M R Candelore, E Rands, W S Hill, R A Dixon, Conserved aspartic acid residues 79 and 113 of the beta-adrenergic receptor have different roles in receptor function. Journal of Biological Chemistry. ,vol. 263, pp. 10267- 10271 ,(1988) , 10.1016/S0021-9258(19)81509-0
K. E. Asin, M. Michaelides, A. Nikkel, L. Hodges, T. Miller, Chun Wel Lin, S. Didomenico, M. Williams, D. R. Britton, L. Smith, D. Witte, B. Bianchi, P. Jenner, L. Mahan, J. Mikusa, K. Shiosaki, Yufeng Hong, M. Stashko, ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease. Journal of Pharmacology and Experimental Therapeutics. ,vol. 276, pp. 150- 160 ,(1996)
Matthew S Lawrence, D Eugene Redmond Jr, John D Elsworth, JR Taylor, RH Roth, None, The D1 receptor antagonist, SCH 23390, induces signs of parkinsonism in African green monkeys Life Sciences. ,vol. 49, ,(1991) , 10.1016/0024-3205(91)90299-Q
A Cross, Preferential inhibition of ligand binding to calf striatal dopamine D1 receptors by SCH 23390 Neuropharmacology. ,vol. 22, pp. 1327- 1329 ,(1983) , 10.1016/0028-3908(83)90208-3